• The blockbuster popularity of GLP-1 medications has everyone talking about them, from promotionby Senera Williamsto satireon South Park. • That heightened profile brings attention more to all aspects of the treatment, from the profound role it plays in improving people’s ability to manage obesity and cardiovascular risk, to indications of potential side effects and risks not revealed through clinical studies. • With the latter aspect, GLP-1s are providing an important reminder of an essential and oft-underappreciated aspect of any drug or medical treatment development: ongoing post-market surveillance. • MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes How can AI benefit and improve patient outcome in the emergency department? • Watch the latest episode to find out. • This crucial phase of development following a drug’s release allows pharmaceutical companies (as well as the FDA and other regulatory agencies) to actively monitor the safety, effectiveness, and use of a new treatment in the “real-world.” This evaluation is essential to understand use in diverse populations, off-label and special groups experiences, and to catch issues that may have been missed in clinical trials, such as rare or long-term adverse effects.
Article Summaries:
- The blockbuster popularity of GLP-1 medications has everyone talking about them, from promotion by Senera Williams to satire on South Park. That heightened profile brings attention more to all aspects of the treatment, from the profound role it plays in improving people’s ability to manage obesity and cardiovascular risk, to indications of potential side effects and risks not revealed through clinical studies. With the latter aspect, GLP-1s are providing an important reminder of an essential and oft-underappreciated aspect of any drug or medical treatment development: ongoing post-market surve
Sources: